SANUWAVE Announces Plans to Attend a Total of Seven Medical and Investor Conferences in March, April and May

Suwanee, GA - (NewMediaWire) - March 13, 2019 - SANUWAVE Health, Inc. (OTCQB: SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, is excited to announce the following conference plans for this March, April and May consisting of 5 medical conferences and 2 investor relations conferences:

Medical Conferences

March 14 – 17, 2019 at KIMES in Seoul, Korea. SANUWAVE will take the opportunity to showcase its successful disruption in the medical device industry at a venue where 1,200 domestic and overseas manufacturers present new technology and products. KIMES is a fantastic place for networking and for SANUWAVE to share its impact in the fast-developing medical market. Kevin Richardson, CEO, and Chairman of the Board will be in attendance at Booth D324. 

April 26- 27, 2019 at MWCM in Greensboro, NC. SANUWAVE is currently making arrangements to attend The Modern Wound Care Management conference which provides the highest quality continuing medical education experience to all clinicians who care for patients with chronic wounds.  SANUWAVE, like others in attendance, focuses on improved patient outcomes by maintaining the most modern and effective management techniques. MWCM has put together an exceptional curriculum and a faculty of wound care experts for networking and education. 

May 7 – May 11, 2019, at SAWC/WHS in San Antonio, TX. SANUWAVE has committed to participate in The Symposium on Advanced Wound Care Spring and Wound Healing Society meeting. The globally attended conference serves as another excellent forum for SANUWAVE to connect with the wound care industry including physicians, nurses, physical therapists, researchers, scientists, podiatrists, and dietitians. SAWC/WHS will host experts in wound care and aim to improve patient outcomes through education, advanced state-of-the-art clinical reviews, and emerging research findings. Visit with SANUWAVE at Booth 736.

May 17 – 18, 2019 at NPWTJ in Poznan, Poland. SANUWAVE is participating in the Negative Pressure Wound Therapy Journal Conference with several other wound care professionals in Poland. SANUWAVE looks forward to the opportunity to connect with industry leaders. 

May 22 – 25, 2019 at ISDF in The Hague, Netherlands. SANUWAVE will attend the International Symposium of the Diabetic Foot (The Diabetic Foot Symposium), which is only held once every four years. It is the largest and most prestigious meeting devoted to lower extremity problems in diabetes. ISDF has accomplished this unique position by bringing together delegates from many specialties and leading experts in various fields, both from all over the world. SANUWAVE’s participation in this event will provide another excellent opportunity to communicate with the experts in the diabetic field.

Investor Relations Conferences

April 1 -2, 2019 at Spring Investor Summit 2019, New York, NY.  The Spring Investor Summit is an exclusive investor relations event dedicated to connecting small and micro-cap companies with high-level, institutional and retail investors. The conference focuses on the most compelling publicly traded companies under $5 billion in market cap across all sectors. SANUWAVE will present at The Essex House at 12:30 pm on April 2. 

April 30 – May 2, 2019, at Planet MicroCap, Las Vegas, NV.  The Planet MicroCap Showcase brings together the most promising companies and the top dealmakers in MicroCap Finance for three days of company presentations, one-on-one meetings, and networking. SANUWAVE is registered to present on May 1 during the first session block. 

CEO and Chairman of the Board Kevin Richardson made the following statement: “We continue to remain excited to showcase the dermaPACE® System globally during these conferences in March, April and May. We have targeted specific events with expert clinicians, cutting-edge education, and vast industry networking opportunities.  Interest in the dermaPACE® System continues to increase and I anticipate an excellent year of growth for SANUWAVE.”

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (OTCQB: SNWV) ( is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE® technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia, and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron®, Evotron® and orthoPACE® devices in Europe, Asia, and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food, and industrial markets.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit


Millennium Park Capital LLC

Christopher Wynne



SANUWAVE Health, Inc.

Kevin Richardson II

Chairman of the Board